SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Coral Laboratories - Quaterly Results

23 May 2023 Evaluate
The sales is pegged at Rs. 114.38 millions for the March 2023 quarter. The mentioned figure indicates a decline of about -43.03% as against Rs. 200.76 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -8.93 millions as compared to Net Profit of Rs. 25.47 millions of corresponding quarter ended March 2022Operating profit Margin for the quarter ended March 2023 slipped to -9.24% as compared to 25.82% of corresponding quarter ended March 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 114.38 200.76 -43.03 781.18 756.11 3.32 781.18 756.11 3.32
Other Income 11.61 15.29 -24.07 68.95 48.14 43.23 68.95 48.14 43.23
PBIDT -9.24 25.82 -135.79 107.07 130.28 -17.82 107.07 130.28 -17.82
Interest 0.18 0.52 -65.38 3.38 1.41 139.72 3.38 1.41 139.72
PBDT -9.42 34.89 -127.00 104.07 138.46 -24.84 104.07 138.46 -24.84
Depreciation 6.80 5.02 35.46 21.80 19.91 9.49 21.80 19.91 9.49
PBT -16.22 29.87 -154.30 82.27 118.55 -30.60 82.27 118.55 -30.60
TAX -7.29 4.40 -265.68 17.81 28.10 -36.62 17.81 28.10 -36.62
Deferred Tax -0.99 3.90 -125.38 -0.39 0.60 -165.00 -0.39 0.60 -165.00
PAT -8.93 25.47 -135.06 64.46 90.45 -28.73 64.46 90.45 -28.73
Equity 35.73 35.73 0.00 35.73 35.73 0.00 35.73 35.73 0.00
PBIDTM(%) -8.08 12.86 -162.81 13.71 17.23 -20.45 13.71 17.23 -20.45

Coral Laboratories Share Price

420.00 -1.20 (-0.28%)
22-Apr-2026 10:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1653.80
Dr. Reddys Lab 1215.95
Cipla 1228.20
Zydus Lifesciences 927.75
Lupin 2307.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×